CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.
News|Articles|October 27, 2025
Sarah McLeod, PhD, breaks down high cure rates with zoliflodacin for uncomplicated gonorrhea
Author(s)Joshua Fitch, Senior Editor , Sarah McLeod, PhD
Fact checked by: Joshua Fitch, Senior Editor
Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in this Q&A with Contemporary Pediatrics.
Advertisement
Advertisement
New subgroup analyses from the global phase 3 zoliflodacin trial highlight the drug’s efficacy against multidrug-resistant Neisseria gonorrhoeae, including ciprofloxacin-resistant strains, across all infection sites and patient subgroups. The data were presented at
Related to this article
Julie Sweetland, PhD, shares strategies to improve vaccine conversations by explaining the science, acknowledging parental concerns, and building trust.
A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.
New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.
With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.
Missed the AAP's new congenital measles guidance? This easy-to-read FAQ covers what pediatric clinicians need to know.
Johanna Chang, MD, offers guidance on vaccination, infection prophylaxis, and clinical warning signs in children receiving biologic therapies.
Advertisement
Advertisement